AxoGen (AXGN) – Research Analysts’ Weekly Ratings Changes

AxoGen (NASDAQ: AXGN) recently received a number of ratings updates from brokerages and research firms:

• 7/30/2026 – AxoGen had its price target raised by HC Wainwright from $50.00 to $53.00. They now have a “buy” rating on the stock.
• 7/30/2026 – AxoGen had its “market outperform” rating reaffirmed by Citigroup Inc..
• 7/30/2026 – AxoGen was given a new $55.00 price target by Truist Financial Corporation.
• 7/30/2026 – AxoGen had its price target raised by Canaccord Genuity Group Inc. from $50.00 to $55.00. They now have a “buy” rating on the stock.
• 7/30/2026 – AxoGen had its price target raised by Citizens Jmp from $50.00 to $55.00. They now have a “market outperform” rating on the stock.
• 7/29/2026 – AxoGen had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $55.00 price target on the stock.
• 7/26/2026 – AxoGen was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/18/2026 – AxoGen was downgraded by Wall Street Zen from “buy” to “hold”.
• 7/4/2026 – AxoGen was upgraded by Wall Street Zen from “hold” to “buy”.

Insiders Place Their Bets

In other AxoGen news, Director Kathy Johnson Weiler sold 14,150 shares of AxoGen stock in a transaction on Friday, August 7th. The shares were sold at an average price of $45.30, for a total value of $640,995.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marc A. Began sold 67,500 shares of the business’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $47.34, for a total transaction of $3,195,450.00. Following the sale, the executive vice president directly owned 50,135 shares of the company’s stock, valued at $2,373,390.90. This represents a 57.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 95,003 shares of company stock valued at $4,482,997 over the last quarter. Company insiders own 2.44% of the company’s stock.

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.